<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210707051812N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-30</date_registration>
      <primary_sponsor>Hamedan University of Medical Sciences</primary_sponsor>
      <public_title>Comparing Nylon and Vicryl Threads on Wound Healing, Scar and Surgeon Satisfaction</public_title>
      <acronym></acronym>
      <scientific_title>A comparative Study of Suturing Inguinal Incision with Vicryl and Nylon Threads on the Wound Healing, Cosmetic Results and Surgeon Satisfaction in Children Undergoing Surgery: A Randomized Clinical Trial Study</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-12-31</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>56</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/67299</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: In this research, Simple Randomization Method and Lottery Type will be used. In this way, a number of folded cards are considered for the Nylon Group and the same number of folded cards are considered for the Vicryl Group. Then the cards are merged and one card is removed and its allocation is recorded. Then the removed card goes back to the cards. Card withdrawal is repeated for the number of samples and a Random Allocation Sequence is obtained. Then each allocation is placed in an Opaque Envelope and the corresponding number is also recorded on the lid of the envelope and arranged in a box according to the sequence. Finally, the first card is taken for the first patient, the second card is taken for the second patient, and so on until the end, Blinding description: Participants and their parents are unaware of which group they are in; However, in order to obtain informed consent, full explanations are provided to them. The generation of random allocation is done by a trusted person outside the research team and the box containing the sequence is provided to the surgeon by the principal investigator. One of the surgeons who is a member of the research team is the only person who knows about the allocation of groups because he performs the suturing. The main researcher has the role of evaluating the outcome and is not aware of the allocation of the groups. In addition, the statistician of the group, who has the role of statistical analysis, does not know about the allocation of groups. In addition, the nurses who take care of the patient in the ward will not be informed about the details of the research groups, and the type of thread cannot be recognized from the wound.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Surgical wound healing. Condition 2: Surgical Wound Scar.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: skin suture is performed once at the end of surgery with Vicryl thread. The thread used is VICRYL RAPIDE W9940 type and produced by ETHICON company. It is manufactured by ETHICON, LLC, CE 0086, XZW9940.1 AND LOT number of AK7988. The thread size is 3.0 and the thread length is 75 cm. The thread needle is 26 mm and 3/8 circle and reverse cutting type. Intervention 2: Control group: Skin suture is done once at the end of surgery with nylon thread. The thread used is produced by TEB KEYHAN company. It is manufactured by NASG TEB KEYHAN, NO 1467/2, Golchin 2, Golriz 2, West Ghazali blvd, Eshtehard Industrial, Karaj, Iran. The thread size is 3.0 and the thread length is 75 cm. The thread needle is 26 mm and 3/8 circle and reverse cutting type.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
After the publication of the article, confidential information such as the names of individuals and organizations will be removed and other information will be provided to the researchers.

When:
Access starts one month after the article is published

To whom:
All researchers

Conditions:
In systematic review studies

Where to obtain:
Corresponding author: jeyranasadihajivand@gmail.com

How to obtain:
Official and academic email to the corresponding author and obtaining permission from the Research Vice-Chancellor of Hamadan University of Medical Sciences by the corresponding author

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Jeyran Asadi Hajivand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 17, Behrouz Mohammadi Alley., Baradarane Ghaedi Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1149774611</zip>
        <telephone>+98 21 7762 1301</telephone>
        <email>jeyranasadihajivand@gmail.com</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Jeyran Asadi hajivand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 17, Behrouz Mohammadi Alley., Ghaedi Brothers Ave</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1149774611</zip>
        <telephone>+98 21 7762 1301</telephone>
        <email>j.asadi@edu.umsha.ac.ir</email>
        <affiliation>Hamedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inguinal Incision should be used for surgery
The wound should be classified as a Clean Wound
The patient's age should be from 1 to 8 years
In case of Inguinal Hernia, It should be Indirect
Hernia should be repaired by Sac Ligation without using Mesh
It should be possible to have In-person and Telephone access with the Patient</inclusion_criteria>
      <agemin>1 year</agemin>
      <agemax>8 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The Patient's Parents do not give Informed Consent
Patients having Congenital Anomaly
Patients having Immunodeficiency Diseases
Patients having Hematology and Coagulation disorders
Patients having Skin Disorders</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: skin suture is performed once at the end of surgery with Vicryl thread. The thread used is VICRYL RAPIDE W9940 type and produced by ETHICON company. It is manufactured by ETHICON, LLC, CE 0086, XZW9940.1 AND LOT number of AK7988. The thread size is 3.0 and the thread length is 75 cm. The thread needle is 26 mm and 3/8 circle and reverse cutting type.</i_keyword>
      <i_keyword>Control group: Skin suture is done once at the end of surgery with nylon thread. The thread used is produced by TEB KEYHAN company. It is manufactured by NASG TEB KEYHAN, NO 1467/2, Golchin 2, Golriz 2, West Ghazali blvd, Eshtehard Industrial, Karaj, Iran. The thread size is 3.0 and the thread length is 75 cm. The thread needle is 26 mm and 3/8 circle and reverse cutting type.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Wound healing score in REEDA scale. Timepoint: in 24 hours after the operation and on the third, fifth and seventh days after the operation. Method of measurement: REEDA wound healing scale.</prim_outcome>
      <prim_outcome>Scar score in Vancouver Scar Scale. Timepoint: 15th and 30th day after the operation. Method of measurement: Vancouver Scar Scale.</prim_outcome>
      <prim_outcome>Surgeon satisfaction. Timepoint: 30th day after the operation. Method of measurement: A 5-point Likert scale developed by the researcher.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Hamedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-12-04</approval_date>
        <contact_name>Ethics committee of Hamadan University of Medical Sciences</contact_name>
        <contact_address>No. 17, Behrouz Mohammadi Alley., Baradaranr Ghaedi Ave Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
